Reporter brief
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
What happened
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy or safety results are reported in the provided text, so no claims about whether these agents actually improve BMAC outcomes can be evaluated
- The study design is described prospectively but as an ongoing trial protocol rather than completed results, so clinical benefit remains unknown
- Without reported data on primary endpoints, sample size achieved, or participant characteristics, the evidentiary value of this trial cannot be assessed
Study design and sample
Rct; Human.
Patients with osteoarthritis of the knee
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.